Fasting Hyperglycaemia Study

OVERVIEW

The Fasting Hyperglycaemia Study (FHS) was a six-year, prospective, randomised, placebo-controlled study in subjects who had two consecutive fasting plasma glucose levels in the range 5.5 to 7.7 mmol/L and were thought to be at risk of developing diabetes. The primary aim of the trial was to determine whether deterioration in glycaemic tolerance towards diabetes can be delayed or prevented using an insulin secretagogue (sulphonylurea) or reinforced healthy living advice.

RESULTS

The results of the FHS trial where presented at the EASD meeting in Jerusalem on 19 September 2000.